Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients

Next Previous
Trial Profile

A Randomised, Double-blind, Placebo-controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Molgramostim (Primary)
  • Indications Autoimmune disorders; Pulmonary alveolar proteinosis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPALA
  • Sponsors Savara Pharmaceuticals; Serendex Pharmaceuticals

    • Most Recent Events

    • 11 Jul 2022 According to a Savara Pharmaceuticals media release, data from the study will be presented at the European Respiratory Society (ERS) International Congress 2022. The full content of the abstract will be available in the Congress's online program and will be published in a supplement of the European Respiratory Journal (ERJ) by the end of November 2022.
    • 08 Sep 2020 Results presented in a Savara Pharmaceuticals media release.
    • 08 Sep 2020 According to a Savara Pharmaceuticals media release, results from the this study were published online in New England Journal of Medicine.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top